Genomic and proteomic characterization of YDOV-157, a newly established human epithelial ovarian cancer cell line

Abstract

The existence of several model systems with which to investigate a particular disease is advantageous for researchers. This
is especially true for ovarian cancer, which, due to its complex and heterogeneous nature, inherently requires a large number
of model systems. Here, we report a new ovarian serous adenocarcinoma cell line, designated YDOV-157, and characterized via
post genomics and post proteomics. In this study, primary culture of tumor cells from ascites was performed and the cells
were immortalized up to at least 60 passages in vitro. We studied the morphologies, cell proliferation, BRCA1/2 mutations,
tumorigenesis capacity, and chemosensitivity of YDOV-157. Using a cDNA microarray, differentially expressed genes were identified
and some of them were validated. Using proteomic analysis, we identified proteins that were differentially expressed in YDOV-157.
The newly derived cell line, designated YDOV-157, grew as a monolayer and the doubling time was 102h. When transplanted into
nude mice, it initiated the formation of tumor masses with microscopic findings identical to those of the primary tumor. Chemosensitivity
test showed that paclitaxel induced the highest chemosensitivity index. In microarray analysis, 2,520 probes were differently
expressed, compared to human ovarian surface epithelial cells (HOSEs). In SYBR Green real-time PCR, the expression of E2F2 (P=0.040) and CRABP2 genes (P=0.030) was significantly higher in the ovarian cancer cell lines than in HOSEs. Furthermore, proteomic analysis showed
that expression of 28 spots was significantly altered between YDOV-157 and HOSE. In conclusion, the newly derived YDOV-157
cell line may be an important research resource for studying cancer cell biology and should also be very useful for developing
new strategies that inhibit cancer cell growth and progression.